NYSE American - Nasdaq Real Time Price USD

MAIA Biotechnology, Inc. (MAIA)

2.0750

+0.0250

+(1.22%)

As of 3:54:08 PM EDT. Market Open.

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

CHICAGO, April 01, 2025--MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

Business Wire 23 days ago

MAIA
+1.22%
Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March?

We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) stands against other cheapest stocks insiders are buying in March. After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, […]

Insider Monkey 27 days ago

MAIA
+1.22%
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know

MAIA Biotechnology, Inc. (MAIA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 28 days ago

MAIA
+1.22%
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

CHICAGO, March 25, 2025--MAIA Biotechnology Announces Poster Presentation at ESMO’s European Lung Cancer Congress 2025

Business Wire 30 days ago

MAIA
+1.22%
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

CHICAGO, March 20, 2025--MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

Business Wire last month

MAIA
+1.22%
MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO

CHICAGO, March 19, 2025--MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO

Business Wire last month

MAIA
+1.22%
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

CHICAGO, February 27, 2025--MAIA to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced NSCLC Patients

Business Wire last month

MAIA
+1.22%
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

CHICAGO, February 26, 2025--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer (NSCLC). Following successful outcomes to date in THIO-101, the expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy

Business Wire last month

MAIA
+1.22%
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

CHICAGO, February 24, 2025--MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

Business Wire last month

MAIA
+1.22%
MAIA Biotechnology Announces Private Placement of $2,715,000

CHICAGO, February 18, 2025--MAIA Biotechnology Announces Private Placement of $2,715,000

Business Wire 2 months ago

MAIA
+1.22%
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

CHICAGO, February 04, 2025--MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

Business Wire 2 months ago

MAIA
+1.22%
MAIA Biotechnology to Present at Biotech Showcase 2025

CHICAGO, January 10, 2025--MAIA Biotechnology to Present at Biotech Showcase 2025

Business Wire 3 months ago

MAIA
+1.22%
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

CHICAGO, January 07, 2025--MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

Business Wire 3 months ago

MAIA
+1.22%
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

CHICAGO, December 19, 2024--MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

Business Wire 4 months ago

MAIA
+1.22%
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

CHICAGO, December 16, 2024--MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

Business Wire 4 months ago

MAIA
+1.22%
MAIA Biotechnology Announces Private Placement of Approximately $950,000

CHICAGO, December 09, 2024--MAIA Biotechnology Announces Private Placement of Approximately $950,000

Business Wire 4 months ago

MAIA
+1.22%
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

CHICAGO, December 03, 2024--MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

Business Wire 4 months ago

MAIA
+1.22%
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

CHICAGO, November 07, 2024--MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

Business Wire 5 months ago

MAIA
+1.22%
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CHICAGO, November 05, 2024--MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the SITC 39th Annual Meeting

Business Wire 5 months ago

MAIA
+1.22%
MAIA Biotechnology Announces $2.44 Million Private Placement

CHICAGO, October 28, 2024--MAIA Biotechnology Announces $2.44 Million Private Placement

Business Wire 5 months ago

MAIA
+1.22%

Performance Overview

Return	MAIA	S&P 500 (^GSPC)
YTD	+4.80%	-6.68%
1-Year	-22.86%	+8.23%
3-Year	-49.39%	+28.49%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MAIA Biotechnology, Inc. (MAIA)

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March?

MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

MAIA Biotechnology Announces Private Placement of $2,715,000

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology to Present at Biotech Showcase 2025

MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

MAIA Biotechnology Announces Private Placement of Approximately $950,000

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

MAIA Biotechnology Announces $2.44 Million Private Placement

Performance Overview